Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D8MS6C
|
|||
| Drug Name |
BGB-15025
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
| Company |
BeiGene
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | MEK kinase kinase 1 (MAP4K1) | Target Info | Inhibitor | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04649385) BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.